

PARTICULARS TO APPEAR ON THE OUTER PACKAGE - CARTON

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Prednidale 25 mg Tablets for dogs

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

1 tablet contains:
Prednisolone 25 mg

3. PHARMACEUTICAL FORM

Tablets

4. PACKAGE SIZE

100 tablets

5. TARGET SPECIES

Dogs

6. INDICATION(S)

For the treatment of inflammatory and allergic diseases in dogs.

7. METHOD AND ROUTE(S) OF ADMINISTRATION

For oral administration only.

Dose: 0.1 – 2.0 mg prednisolone per kg body weight per day.

The lowest effective dose must be used.

These tablets are not appropriate when dosing small dogs at the lower recommended dosage rate and the 5 mg tablet strength may be required.

Treatment should not be withdrawn suddenly. A gradual reduction of dosage is recommended.

Dogs should be dosed in the morning to coincide with the endogenous cortisol peak.

8. WITHDRAWAL PERIOD

9. SPECIAL WARNING(S), IF NECESSARY

Do not use in pregnant animals, those suffering from diabetes mellitus, in animals with renal insufficiency or those with corneal ulceration.

Do not use in animals being vaccinated with products containing live organisms.

Treatment may render concurrent vaccination inoperative.

Appropriate therapy should be instituted in animals with concurrent bacterial infections.

Use of corticosteroids may exacerbate viral infections.

Prolonged use of high dose levels may result in undesirable effects.

Do not withdraw corticosteroid therapy suddenly.
Signs of overdosage should be treated symptomatically.
Serum electrolytes should be monitored.
Consideration should be given to the use of antimicrobials due to the potential suppression of the immune system.
Corticosteroids are not recommended for use in pregnant animals.
Studies in laboratory animals have shown administration during early pregnancy may cause foetal abnormalities.
Administration during the later stages of pregnancy may cause abortion or early parturition.
Gastrointestinal ulceration may be exacerbated by corticosteroids in animals given non-steroidal anti-inflammatory drugs (NSAIDs).
Regular veterinary re-evaluation of animals on prolonged courses of prednisolone is recommended.

Gloves should be worn to administer the product and you should wash hands immediately after administration of the product.

In the event of accidental ingestion, particularly by a child, seek medical advice and show the doctor the label or package leaflet.

See package leaflet for further details.

10. EXPIRY DATE

11. SPECIAL STORAGE CONDITIONS

Do not store above 25°C.
Store in tightly closed original container.
Store in a dry place.

12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority.

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IF

For animal treatment only.

POM-V Prescription Only Medicine - Veterinarian

To be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Dechra Regulatory B.V.
Handelsweg 25
5531 AE Bladel
The Netherlands

Local representative:
Dechra Veterinary Products Limited
Sansaw Business Park
Hadnall
Shrewsbury
Shropshire
SY4 4AS

16. MARKETING AUTHORISATION NUMBER

Vm 50406/5029

17. MANUFACTURER’S BATCH NUMBER

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE - LABEL

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Prednidale 25 mg Tablets for dogs

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

1 tablet contains:
Prednisolone 25 mg

3. PHARMACEUTICAL FORM

Tablets

4. PACKAGE SIZE

100 tablets

5. TARGET SPECIES

Dogs

6. INDICATION(S)

For the treatment of inflammatory and allergic diseases in dogs.

7. METHOD AND ROUTE(S) OF ADMINISTRATION

For oral administration only.
Treatment should not be withdrawn suddenly. A gradual reduction of dosage is recommended.

8. WITHDRAWAL PERIOD

9. SPECIAL WARNING(S), IF NECESSARY

Do not use in pregnant animals, those suffering from diabetes mellitus, in animals with renal insufficiency or those with corneal ulceration.
Do not use in animals being vaccinated with products containing live organisms. Treatment may render concurrent vaccination inoperative.
Appropriate therapy should be instituted in animals with concurrent bacterial infections.
Use of corticosteroids may exacerbate viral infections.
Prolonged use of high dose levels may result in undesirable effects.
Do not withdraw corticosteroid therapy suddenly.
Signs of overdosage should be treated symptomatically.
Serum electrolytes should be monitored.
Consideration should be given to the use of antimicrobials due to the potential suppression of the immune system.

Corticosteroids are not recommended for use in pregnant animals. Studies in laboratory animals have shown administration during early pregnancy may cause foetal abnormalities. Administration during the later stages of pregnancy may cause abortion or early parturition. Gastrointestinal ulceration may be exacerbated by corticosteroids in animals given non-steroidal anti-inflammatory drugs (NSAIDs). Regular veterinary re-evaluation of animals on prolonged courses of prednisolone is recommended.

Gloves should be worn to administer the product and you should wash hands immediately after administration of the product.

In the event of accidental ingestion, particularly by a child, seek medical advice and show the doctor the label or package leaflet.

See package leaflet for further details.

10. EXPIRY DATE

EXP:

11. SPECIAL STORAGE CONDITIONS

Do not store above 25°C.
Store in tightly closed original container.
Store in a dry place.

12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority.

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IF

For animal treatment only.

| |
|-------|
| POM-V |
|-------|

 Prescription Only Medicine - Veterinarian

To be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the reach and site of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Dechra Regulatory B.V.
Handelsweg 25
5531 AE Bladel
The Netherlands

Local representative:
Dechra Veterinary Products Limited
Sansaw Business Park
Hadnall
Shrewsbury
Shropshire
SY4 4AS

16. MARKETING AUTHORISATION NUMBER

Vm 50406/5029

17. MANUFACTURER'S BATCH NUMBER

Lot no:

PACKAGE LEAFLET FOR:

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Dechra Regulatory B.V.
Handelsweg 25
5531 AE Bladel
The Netherlands

Manufacturer responsible for batch release:

Dales Pharmaceuticals
Snaygill Industrial Estate
Keighley Road
Skipton
North Yorkshire
BD23 2RW
United Kingdom

Genera d.d.
Svetonedeljska cesta 2
Kalinovica
10436 Rakov Potok
Croatia

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Prednidale
25 mg
Tablets for dogs
Prednisolone

3. STATEMENT OF THE ACTIVE SUBSTANCE (S) AND OTHER INGREDIENTS

Each tablet contains: Active substance: Prednisolone 25 mg.

White, 11 mm circular tablets.

4. INDICATION(S)

Prednidale 25 mg tablets are indicated in the treatment of inflammatory and allergic diseases, including some autoimmune diseases and some neoplastic conditions, in dogs. Inflammatory, allergic and autoimmune processes may be involved in cutaneous, alimentary, respiratory, musculo-skeletal and haematological manifestation of disease.

5. CONTRAINDICATIONS

Do not use in pregnant animals, those suffering from diabetes mellitus, in animals with renal insufficiency or those with corneal ulceration.

Do not use in animals being vaccinated with products containing live organisms.

6. ADVERSE REACTIONS

Anti-inflammatory corticosteroids, such as prednisolone, are known to exert a wide range of side effects. Whilst single high doses are generally well tolerated, they may induce severe side-effects in long term use. Dosage in medium to long term use should therefore generally be kept to the minimum necessary to control symptoms.

The significant dose related cortisol suppression noticed during therapy is a result of effective doses suppressing the hypothalamic-pituitary-adrenal-axis. Following cessation of treatment, signs of adrenal insufficiency can arise, and this may render the animal unable to deal adequately with stressful situations.

The significant increase in triglycerides noticed can be a part of possible iatrogenic hyperadrenocorticism (Cushing's disease) involving significant alteration of fat, carbohydrate, protein and mineral metabolism, e.g. redistribution of body fat, increase in body weight, muscle weakness, wastage and osteoporosis may result. Cortisol suppression and an increase in plasma triglycerides is a possible side-effect of medication with corticoids. Weight gain has been reported in very rare cases, in post-authorisation experience.

Changes in biochemical, haematological and liver parameters, such as significant effects on alkaline phosphatase (increase), lactate dehydrogenase (decrease), aspartate transaminase (decrease), albumin (increase), eosinophils, lymphocytes (decrease), segmented neutrophils (increase), and serum hepatic enzymes (increase) are probably associated with the use of prednisolone. Changes in haematological parameters have been reported in rare cases and changes in biochemical and liver parameters in very rare cases, in post authorisation experience.

Polyuria and polydipsia have been reported in rare cases and polyphagia in very rare cases, in post authorisation experience and may be caused by systemically administered corticosteroids, particularly during the early stages of therapy. Sodium and water retention and hypokalaemia may be caused by some corticosteroids in long term use. Hypokalemia has been reported in very rare cases, in post authorisation experience.

Deposition of calcium in the skin (calcinosis cutis) has been caused by systemic corticosteroids.

Wound healing may be delayed during corticosteroid use and the immunosuppressant actions may weaken resistance to, or exacerbate existing infections.

Gastrointestinal ulceration has been reported in very rare cases in animals treated with corticosteroids in post authorisation experience and may be exacerbated by steroids in animals given non-steroidal anti-inflammatory drugs. Inhibition of longitudinal growth of bones; skin atrophy; diabetes mellitus; behavioral disorders (excitation and depression), pancreatitis, decrease in thyroid hormone synthesis; and increase in parathyroid hormone synthesis are o. ther adverse reactions that may occur. Excitation has been reported in very rare cases, in post authorisation experience.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

7. TARGET SPECIES

Dogs

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

For oral administration in dogs.

Dose: 0.1 – 2.0 mg prednisolone per kg body weight per day.

The lowest effective dose must be used.

These tablets are not appropriate when dosing small dogs at the lower recommended dosage rates and the 5 mg tablet strength may be required.

Treatment should not be withdrawn suddenly.

A gradual reduction of dosage is recommended.

Dogs should be dosed in the morning to coincide with the endogenous cortisol peak.

A single administration may be sufficient for some conditions such as anaphylaxis.

For more general treatment, administration for between one and three weeks at the above dosage levels may be required.

Dosage levels should be monitored carefully to ensure that the lowest effective dose is used.

Alternate-day therapy should be implemented to control symptoms if possible, to minimise the risk of adrenal insufficiency.

Higher dose levels may be used in animals with tumours responsive to corticosteroid therapy. In these cases, the dosage levels of between 20 mg per m² and 60 mg per m² have been found to be useful.

The potential risks associated with these high dose levels should be assessed before commencing treatment.

Gloves should be worn to administer the product and you should wash hands immediately after administration of the product.

9. ADVICE ON CORRECT ADMINISTRATION

10. WITHDRAWAL PERIOD(S)

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.
Do not store above 25°C.
Store in tightly closed original container.
Store in a dry place.

12. SPECIAL WARNING(S)

For Animal Treatment Only

Treatment may render concurrent vaccination inoperative.

Appropriate therapy should be instituted in animals with concurrent bacterial infections.

Use of corticosteroids may exacerbate viral infections.

Prolonged use at high dose levels may result in undesirable effects.

Do not withdraw corticosteroid therapy suddenly.

Signs of overdosage should be treated symptomatically.

Serum electrolytes should be monitored.

Consideration should be given to the use of antimicrobials due to the potential suppression of the immune system.

Corticosteroids, including prednisolone, have a wide range of effects.

Polydipsia, polyuria and polyphagia may develop, particularly during the early stages of therapy.

In the longer term, iatrogenic Cushing's disease may develop.

Gastrointestinal ulceration has been reported in animals treated with corticosteroids.

Steroids may cause enlargement of the liver (hepatomegaly) with increased serum hepatic enzymes.

Pharmacologically active dose levels may lead to atrophy of the adrenal cortex, resulting in adrenal insufficiency. This may become apparent particularly after withdrawal of corticosteroid treatment.

Adrenal insufficiency may be minimised by institution of alternate-day therapy if practical.

The dosage should be reduced and withdrawn gradually to avoid precipitation of adrenal insufficiency.

Corticosteroids are not recommended for use in pregnant animals. Studies in laboratory animals have shown that administration during early pregnancy may cause foetal abnormalities. Administration during the later stages of pregnancy may cause abortion or early parturition.

Insignificant amounts of prednisolone are generally eliminated in the milk of lactating animals, and therefore such use is not contraindicated.

Gastrointestinal ulceration may be exacerbated by corticosteroids in animals given non-steroidal anti-inflammatory drugs (NSAIDs).

Regular veterinary re-evaluation of animals on prolonged courses of prednisolone is recommended.

In the event of accidental ingestion, particularly by a child, seek medical advice and show the doctor the label or package leaflet.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority.

14. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

15. OTHER INFORMATION

POM-V

Prescription Only Medicine – Veterinarian

To be supplied only on veterinary prescription.

Package quantities: 100 tablets per container.

Vm 50406/5029

For information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

Dechra Veterinary Products Limited
Sansaw Business Park, Hadnall
Shrewsbury
Shropshire
SY4 4AS
United Kingdom

Gavin Hall
Approved: 23 October 2025